Thanks for those reference points bear....

I'm wondering if Resverlogix can really be said to have taken 208 to Phase 3 "on its own" given the involvement of HL, both in terms of the cash they've put up as well as trial sites in China.  We are over that FR Rule threshold of $300 million USD...currently at about $475 million USD.  It seems that with cancer drugs the success rate is about the same 54/55% regardless of how much over $300 million the company's market cap is...between $300 million and $1 billion or $1 billion and up, the success rate is actually marginally better (one single %) for the $300 to $1 billion group.